RU2018100123A - Иммуногенные композиции, содержащие конъюгированные антигены капсульного сахарида, наборы, содержащие эти композиции, и их применения - Google Patents
Иммуногенные композиции, содержащие конъюгированные антигены капсульного сахарида, наборы, содержащие эти композиции, и их применения Download PDFInfo
- Publication number
- RU2018100123A RU2018100123A RU2018100123A RU2018100123A RU2018100123A RU 2018100123 A RU2018100123 A RU 2018100123A RU 2018100123 A RU2018100123 A RU 2018100123A RU 2018100123 A RU2018100123 A RU 2018100123A RU 2018100123 A RU2018100123 A RU 2018100123A
- Authority
- RU
- Russia
- Prior art keywords
- paragraphs
- glycoconjugate
- set according
- pneumoniae
- immunogenic composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 30
- 230000002163 immunogen Effects 0.000 title claims 23
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 150000001720 carbohydrates Chemical class 0.000 title 1
- 238000002255 vaccination Methods 0.000 claims 4
- 229960003983 diphtheria toxoid Drugs 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 229960000814 tetanus toxoid Drugs 0.000 claims 3
- 239000002671 adjuvant Substances 0.000 claims 2
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 claims 1
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 claims 1
- 241000606768 Haemophilus influenzae Species 0.000 claims 1
- 101710188053 Protein D Proteins 0.000 claims 1
- 101710132893 Resolvase Proteins 0.000 claims 1
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 229940047650 haemophilus influenzae Drugs 0.000 claims 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
- C08H1/00—Macromolecular products derived from proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Claims (31)
1. Набор, содержащий: (а) первую иммуногенную композицию, содержащую по меньшей мере один гликоконъюгат, выбранный из группы, состоящей из гликоконъюгата S. pneumoniae серотипа 15В, гликоконъюгата S. pneumoniae серотипа 22F, гликоконъюгата S. pneumoniae серотипа 33F, гликоконъюгата S. pneumoniae серотипа 12F, гликоконъюгата S. pneumoniae серотипа 10А, гликоконъюгата S. pneumoniae серотипа 11А и гликоконъюгата S. pneumoniae серотипа 8, где указанная композиция представляет собой 1, 2, 3, 4, 5, 6 или 7-валентную пневмококковую конъюгатную композицию; и (б) вторую иммуногенную композицию, содержащую по меньшей мере один гликоконъюгат Streptococcus pneumoniae серотипа, выбранного из группы, состоящей из серотипов 1, 3, 4, 5, 6А, 6В, 7F, 9V, 14, 18С, 19А, 19F и 23F, для совместного, сопутствующего, параллельного или последовательного введения первой и второй иммуногенных композиций.
2. Набор по п. 1, где указанная первая иммуногенная композиция содержит гликоконъюгат S. pneumoniae серотипа 15В, гликоконъюгат S. pneumoniae серотипа 22F, гликоконъюгат S. pneumoniae серотипа 33F, гликоконъюгат S. pneumoniae серотипа 12F, гликоконъюгат S. pneumoniae серотипа 10А, гликоконъюгат S. pneumoniae серотипа 11А и гликоконъюгат S. pneumoniae серотипа 8, и где указанная композиция представляет собой 7-валентную пневмококковую конъюгатную композицию.
3. Набор по любому из пп. 1-2, где указанные гликоконъюгаты указанной первой иммуногенной композиции индивидуально конъюгированы с CRM197 (перекрестно-реагирующий материал 197).
4. Набор по любому из пп. 1-3, где указанная первая иммуногенная композиция дополнительно содержит по меньшей мере один адъювант.
5. Набор по любому из пп. 1-4, где указанная вторая иммуногенная композиция содержит гликоконъюгаты S. pneumoniae серотипов 4, 6В, 9V, 14, 18С, 19F и 23F.
6. Набор по любому из пп. 1-4, где указанная вторая иммуногенная композиция содержит гликоконъюгаты S. pneumoniae серотипов 1, 4, 5, 6В, 7F, 9V, 14, 18С, 19F и 23F.
7. Набор по любому из пп. 1-4, где указанная вторая иммуногенная композиция содержит гликоконъюгаты S. pneumoniae серотипов 1, 3, 4, 5, 6А, 6В, 7F, 9V, 14, 18С, 19А, 19F и 23F.
8. Набор по любому из пп. 5-7, где указанные гликоконъюгаты S. pneumoniae серотипов 4, 6В, 9V, 14, 18С, 19F и 23F конъюгированы с CRM197.
9. Набор по любому из пп. 6-7, где указанные гликоконъюгаты S. pneumoniae серотипов 1, 5 и 7F конъюгированы с CRM197.
10. Набор по п. 7, где указанные гликоконъюгаты S. pneumoniae серотипов 3, 6А и 19А конъюгированы с CRM197.
11. Набор по п.7, где указанные гликоконъюгаты S. pneumoniae серотипов 1, 3, 4, 5, 6А, 6В, 7F, 9V, 14, 18С, 19А, 19F и 23F конъюгированы с CRM197.
12. Набор по любому из пп. 6-7, где указанные гликоконъюгаты S. pneumoniae серотипов 1, 4, 5, 6В, 7F, 9V, 14 и 23F индивидуально конъюгированы с PD (белок D Haemophilus influenzae).
13. Набор по любому из пп. 6-7, где указанный гликоконъюгат S. pneumoniae серотипа 18С конъюгирован с ТТ (столбнячный анатоксин).
14. Набор по любому из пп. 6-7, где указанный гликоконъюгат S. pneumoniae серотипа 19F конъюгирован с DT (дифтерийный анатоксин).
15. Набор по любому из пп. 6-7, где указанные гликоконъюгаты S. pneumoniae серотипов 1, 4, 5, 6В, 7F, 9V, 14 и/или 23F индивидуально конъюгированы с PD, указанный гликоконъюгат S. pneumoniae серотипа 18С конъюгирован с ТТ и указанный гликоконъюгат S. pneumoniae серотипа 19F конъюгирован с DT.
16. Набор по любому из пп. 1-15, где указанная вторая иммуногенная композиция представляет собой 7, 8, 9, 10, 11, 12, 13, 14 или 15-валентную пневмококковую конъюгатную композицию.
17. Набор по любому из пп. 1-16, где указанная вторая иммуногенная композиция представляет собой 13-валентную пневмококковую конъюгатную композицию, где указанные 13 конъюгатов состоят из гликоконъюгатов S. pneumoniae серотипов 1, 3, 4, 5, 6А, 6В, 7F, 9V, 14, 18С, 19А, 19F и 23F, индивидуально конъюгированных с CRM197.
18. Набор по любому из пп. 1-17, где указанная вторая иммуногенная композиция дополнительно содержит по меньшей мере один адъювант.
19. Набор по любому из пп. 1-18 для совместного введения первой и второй иммуногенных композиций.
20. Набор по любому из пп. 1-18 для применения в способе параллельного введения первой и второй иммуногенных композиций.
21. Набор по любому из пп. 1-18 для применения в способе сопутствующего введения первой и второй иммуногенных композиций.
22. Набор по любому из пп. 19-21, где схема вакцинации с указанным совместным, параллельным или сопутствующим введением представляет собой схему многократных доз.
23. Набор по п. 22, где указанная схема многократных доз состоит из по меньшей мере одной дозы (например, 1, 2 или 3 доз) в первый год жизни, за которой следует по меньшей мере одна доза для ребенка, начинающего ходить.
24. Набор по любому из пп. 1-18 для применения в способе последовательного введения первой и второй иммуногенных композиций.
25. Набор по п. 24, где схема вакцинации с указанным последовательным введением состоит из серии из 2, 3, 4, 5, 6, 7 или 8 доз.
26. Набор по любому из пп. 24-25, где схема вакцинации состоит из последовательного введения:
(а) первой иммуногенной композиции и
(б) параллельного или сопутствующего введения первой иммуногенной композиции со второй иммуногенной композицией.
27. Набор по любому из пп. 24-25, где схема вакцинации состоит из последовательного введения:
(а) второй иммуногенной композиции и
(б) параллельного или сопутствующего введения первой иммуногенной композиции со второй иммуногенной композицией.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562194965P | 2015-07-21 | 2015-07-21 | |
US62/194,965 | 2015-07-21 | ||
PCT/IB2016/054217 WO2017013548A1 (en) | 2015-07-21 | 2016-07-18 | Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2018100123A3 RU2018100123A3 (ru) | 2019-08-21 |
RU2018100123A true RU2018100123A (ru) | 2019-08-21 |
RU2721128C2 RU2721128C2 (ru) | 2020-05-18 |
Family
ID=56507633
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2018100123A RU2721128C2 (ru) | 2015-07-21 | 2016-07-18 | Иммуногенные композиции, содержащие конъюгированные антигены капсульного сахарида, наборы, содержащие эти композиции, и их применения |
Country Status (22)
Country | Link |
---|---|
US (3) | US10124050B2 (ru) |
EP (1) | EP3325008A1 (ru) |
JP (3) | JP6994453B2 (ru) |
KR (3) | KR102225282B1 (ru) |
CN (1) | CN108367063A (ru) |
AR (1) | AR105402A1 (ru) |
AU (2) | AU2016295566B2 (ru) |
BR (1) | BR112018000087A2 (ru) |
CA (1) | CA2936378A1 (ru) |
CO (1) | CO2018000503A2 (ru) |
HK (1) | HK1257816A1 (ru) |
IL (2) | IL303998A (ru) |
MX (2) | MX2018000867A (ru) |
MY (1) | MY192183A (ru) |
NZ (1) | NZ739007A (ru) |
PE (1) | PE20180657A1 (ru) |
PH (1) | PH12018500037A1 (ru) |
RU (1) | RU2721128C2 (ru) |
SG (1) | SG10202005253TA (ru) |
TW (4) | TWI684460B (ru) |
WO (1) | WO2017013548A1 (ru) |
ZA (2) | ZA201800197B (ru) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014124228A1 (en) | 2013-02-07 | 2014-08-14 | Children's Medical Center Corporation | Protein antigens that provide protection against pneumococcal colonization and/or disease |
RU2743793C1 (ru) * | 2014-01-21 | 2021-02-26 | Пфайзер Инк. | Капсульные полисахариды Streptococcus pneumoniae и их конъюгаты |
US11160855B2 (en) * | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
MX371454B (es) * | 2014-01-21 | 2020-01-29 | Pfizer | Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos. |
KR102225282B1 (ko) * | 2015-07-21 | 2021-03-10 | 화이자 인코포레이티드 | 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도 |
EP3377098A1 (en) * | 2015-11-20 | 2018-09-26 | Pfizer Inc | Immunogenic compositions for use in pneumococcal vaccines |
US11058757B2 (en) | 2016-03-31 | 2021-07-13 | Pogona, LLC | Saccharide-polypeptide conjugate compositions and methods of use thereof |
US11951165B2 (en) | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
EP3576784A4 (en) | 2017-01-31 | 2020-11-11 | Merck Sharp & Dohme Corp. | PROCESS FOR THE PRODUCTION OF POLYSACCHARIDE PROTEIN CONJUGATES |
CA3052621A1 (en) | 2017-02-03 | 2018-08-09 | Schadeck, Eva Barbara | Haemophilus influenzae saccharide-carrier conjugate compositions and uses thereof |
WO2018156491A1 (en) * | 2017-02-24 | 2018-08-30 | Merck Sharp & Dohme Corp. | Enhancing immunogenicity of streptococcus pneumoniae polysaccharide-protein conjugates |
US10729763B2 (en) | 2017-06-10 | 2020-08-04 | Inventprise, Llc | Mixtures of polysaccharide-protein pegylated compounds |
AU2018280272C1 (en) | 2017-06-10 | 2021-05-06 | Inventprise, Inc. | Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity |
CN117736348A (zh) * | 2017-09-07 | 2024-03-22 | 默沙东有限责任公司 | 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途 |
EP3678653A4 (en) | 2017-09-07 | 2021-05-26 | Merck Sharp & Dohme Corp. | ANTIPNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN POLYSACCHARIDE-CARRIER PROTEIN IMMUNOGENIC CONJUGATES |
KR20200051004A (ko) * | 2017-09-07 | 2020-05-12 | 머크 샤프 앤드 돔 코포레이션 | 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도 |
KR20200051005A (ko) | 2017-09-07 | 2020-05-12 | 머크 샤프 앤드 돔 코포레이션 | 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도 |
US11524076B2 (en) | 2017-09-07 | 2022-12-13 | Merck Sharp & Dohme Llc | Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates |
EP3678694A4 (en) * | 2017-09-07 | 2021-10-20 | Merck Sharp & Dohme Corp. | METHOD FOR FORMULATING PNEUMOCOCCAL POLYSACCHARIDES FOR CONJUGATION TO A CARRIER PROTEIN |
US20200330579A1 (en) * | 2017-10-04 | 2020-10-22 | Liffey Biotech Limited | Saccharide-polypeptide conjugate compositions and methods of use thereof |
CA3084436A1 (en) | 2017-12-06 | 2019-07-18 | Merck Sharp & Dohme Corp. | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
EP3787674A4 (en) * | 2018-04-30 | 2022-01-26 | Merck Sharp & Dohme Corp. | PROCESS FOR THE PRODUCTION OF STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE CAPSULAR PROTEIN CONJUGATES FROM LYOSPHERES |
JP7397000B2 (ja) | 2018-04-30 | 2023-12-12 | メルク・シャープ・アンド・ドーム・エルエルシー | 凍結乾燥変異ジフテリア毒素のジメチルスルホキシド中均一溶液を提供する方法 |
TW202019470A (zh) | 2018-09-12 | 2020-06-01 | 美商艾芬尼維克斯公司 | 多價肺炎球菌疫苗 |
AU2019401535B2 (en) | 2018-12-19 | 2023-12-14 | Merck Sharp & Dohme Llc | Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
CN110302375A (zh) * | 2019-06-27 | 2019-10-08 | 康希诺生物股份公司 | 一种糖缀合物及其用途 |
CN112741901A (zh) * | 2019-10-31 | 2021-05-04 | 北京科兴中维生物技术有限公司 | 一种含有5型肺炎链球菌荚膜多糖的疫苗及其制备方法 |
CA3161857A1 (en) * | 2019-11-22 | 2021-05-27 | Glaxosmithkline Biologicals Sa | Dosage and administration of a bacterial saccharide glycoconjugate vaccine |
EP4150104A1 (en) * | 2020-05-14 | 2023-03-22 | Serum Institute Of India Private Limited | Methods for simultaneous fragmentation and purification of bacterial polysaccharides |
GB202016165D0 (en) | 2020-10-12 | 2020-11-25 | Optivalent Ltd | Vaccine |
WO2023051684A1 (zh) * | 2021-09-29 | 2023-04-06 | 北京大学 | 一种细菌荚膜寡糖衍生物及其制备方法、药物组合物和用途 |
GB2614916A (en) * | 2022-01-25 | 2023-07-26 | Optivalent Ltd | Intradermal vaccine complement |
CN115671274B (zh) * | 2022-09-29 | 2024-03-12 | 普大生物科技(泰州)有限公司 | 一种载体蛋白与多糖共价键连接成结合物的方法及应用 |
Family Cites Families (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4686102A (en) * | 1984-04-12 | 1987-08-11 | American Cyanamid Company | Multivalent pneumococcal vaccine and preparation thereof |
US4709017A (en) | 1985-06-07 | 1987-11-24 | President And Fellows Of Harvard College | Modified toxic vaccines |
US4950740A (en) | 1987-03-17 | 1990-08-21 | Cetus Corporation | Recombinant diphtheria vaccines |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
GB8815795D0 (en) | 1988-07-02 | 1988-08-10 | Bkl Extrusions Ltd | Glazing bead |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
EP0378881B1 (en) | 1989-01-17 | 1993-06-09 | ENIRICERCHE S.p.A. | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
CA2063271A1 (en) | 1989-07-14 | 1991-01-15 | Subramonia Pillai | Cytokine and hormone carriers for conjugate vaccines |
IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
ATE128628T1 (de) | 1990-08-13 | 1995-10-15 | American Cyanamid Co | Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff. |
ATE245446T1 (de) | 1992-02-11 | 2003-08-15 | Jackson H M Found Military Med | Dualer träger für immunogene konstrukte |
IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
JP3506431B2 (ja) | 1992-05-06 | 2004-03-15 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ジフテリア毒素受容体結合領域 |
HU219808B (hu) | 1992-06-25 | 2001-08-28 | Smithkline Beecham Biologicals S.A. | Adjuvánst tartalmazó vakcinakompozíció és eljárás annak előállítására |
IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
DE69434079T2 (de) | 1993-03-05 | 2005-02-24 | Wyeth Holdings Corp. | Plasmid zur Herstellung von CRM-Protein und Diphtherie-Toxin |
DE69405551T3 (de) | 1993-03-23 | 2005-10-20 | Smithkline Beecham Biologicals S.A. | 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen |
AU678613B2 (en) | 1993-09-22 | 1997-06-05 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs |
US5416349A (en) | 1993-12-16 | 1995-05-16 | National Semiconductor Corporation | Increased-density flash EPROM that requires less area to form the metal bit line-to-drain contacts |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US5917017A (en) | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
US6455673B1 (en) | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
CA2194761C (en) | 1994-07-15 | 2006-12-19 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
ATE241384T1 (de) | 1995-03-22 | 2003-06-15 | Jackson H M Found Military Med | Herstellung von immunogenen konstrukten unter verwendung von löslichen kohlehydraten, die durch organische cyanylierungs-reagenzien aktiviert wurden |
GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
AUPO517897A0 (en) | 1997-02-19 | 1997-04-11 | Csl Limited | Chelating immunostimulating complexes |
WO1998037919A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS |
US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
EP1003531B1 (en) | 1997-05-20 | 2007-08-22 | Ottawa Health Research Institute | Processes for preparing nucleic acid constructs |
GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
EP1009382B1 (en) | 1997-09-05 | 2003-06-18 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
ES2284247T3 (es) | 1998-04-03 | 2007-11-01 | University Of Iowa Research Foundation | Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos. |
WO1999052549A1 (en) | 1998-04-09 | 1999-10-21 | Smithkline Beecham Biologicals S.A. | Adjuvant compositions |
GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
DE122007000087I1 (de) | 1998-10-16 | 2008-03-27 | Glaxosmithkline Biolog Sa | Adjuvanzsysteme und impfstoffe |
ES2322306T3 (es) | 1998-12-21 | 2009-06-18 | Medimmune, Inc. | Proteinas de streptpcpccus pneumoniae y fragmentos inmunogenicos para vacunas. |
CA2356836C (en) | 1998-12-23 | 2011-09-13 | Shire Biochem Inc. | Novel streptococcus antigens |
AUPP807399A0 (en) | 1999-01-08 | 1999-02-04 | Csl Limited | Improved immunogenic lhrh composition and methods relating thereto |
EP2204186B1 (en) | 1999-02-17 | 2016-04-06 | CSL Limited | Immunogenic complexes and methods relating thereto |
US6936258B1 (en) | 1999-03-19 | 2005-08-30 | Nabi Biopharmaceuticals | Staphylococcus antigen and vaccine |
BR0009163A (pt) | 1999-03-19 | 2001-12-26 | Smithkline Beecham Biolog | Vacina |
JP2002541808A (ja) | 1999-04-09 | 2002-12-10 | テクラブ, インコーポレイテッド | ポリサッカリド結合体ワクチンのための組換えトキシンaタンパク質キャリア |
BRPI0010612B8 (pt) | 1999-04-19 | 2021-05-25 | Smithkline Beecham Biologicals S A | vacinas |
CZ20021045A3 (cs) | 1999-09-24 | 2002-08-14 | Smithkline Beecham Biologicals S. A. | Pomocný prostředek |
KR20020038770A (ko) | 1999-09-24 | 2002-05-23 | 장 스테판느 | 애쥬번트로서의 폴리옥시에틸렌 소르비탄 에스테르와옥톡시놀의 조합물의 용도 및 백신과 관련된 이의 용도 |
GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
IL153558A0 (en) | 2000-06-20 | 2003-07-06 | Shire Biochem Inc | Streptococcus antigens |
GB0108364D0 (en) | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
AU2002309706A1 (en) | 2001-05-11 | 2002-11-25 | Aventis Pasteur, Inc. | Novel meningitis conjugate vaccine |
WO2003024480A2 (en) | 2001-09-14 | 2003-03-27 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
WO2003054007A2 (en) | 2001-12-20 | 2003-07-03 | Shire Biochem Inc. | Streptococcus antigens |
AU2004219910B2 (en) | 2003-03-13 | 2010-06-17 | Glaxosmithkline Biologicals S.A. | Purification process for bacterial cytolysin |
CA2519511A1 (en) | 2003-03-17 | 2004-09-30 | Wyeth Holdings Corporation | Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
GB0323103D0 (en) | 2003-10-02 | 2003-11-05 | Chiron Srl | De-acetylated saccharides |
EP2484374A1 (en) | 2004-07-18 | 2012-08-08 | CSL Limited | Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
CA2574090A1 (en) | 2004-07-18 | 2006-12-21 | Coley Pharmaceutical Group, Ltd. | Methods and compositions for inducing innate immune responses |
GB0421083D0 (en) | 2004-09-22 | 2004-10-27 | Glaxosmithkline Biolog Sa | Purification process |
GB0428394D0 (en) * | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
GB0502095D0 (en) * | 2005-02-01 | 2005-03-09 | Chiron Srl | Conjugation of streptococcal capsular saccharides |
US20070184072A1 (en) | 2005-04-08 | 2007-08-09 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
KR101730748B1 (ko) | 2005-04-08 | 2017-04-26 | 와이어쓰 엘엘씨 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
DK3466982T3 (da) | 2005-04-08 | 2020-08-03 | Wyeth Llc | Separation af forurenende kontaminanter fra streptococcus pneumoniae-polysaccharid ved ph-manipulation |
US7955605B2 (en) | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US8431136B2 (en) * | 2005-06-27 | 2013-04-30 | Glaxosmithkline Biologicals S.A. | Immunogenic composition |
JO2813B1 (en) * | 2005-12-22 | 2014-09-15 | جلاكسو سميث كلاين بايولوجيكالز اس.ايه | A vaccine with multiple pneumococcal saccharides |
TW200806315A (en) * | 2006-04-26 | 2008-02-01 | Wyeth Corp | Novel formulations which stabilize and inhibit precipitation of immunogenic compositions |
AU2007307800C1 (en) | 2006-10-10 | 2014-03-13 | Wyeth Llc | Purification of Streptococcus pneumoniae type 3 polysaccharides |
DK2129693T3 (en) | 2007-03-23 | 2017-02-13 | Wyeth Llc | BRIEF PURIFICATION PROCEDURE FOR THE PREPARATION OF STREPTOCOCCUS PNEUMONIAE-Capsule POLYACCHARIDES |
EA201490303A1 (ru) | 2007-05-02 | 2014-05-30 | Глаксосмитклайн Байолоджикалс С.А. | Вакцина |
CN105267974A (zh) * | 2007-06-20 | 2016-01-27 | 辉瑞爱尔兰制药公司 | 用于缀合疫苗的经过修饰的多糖 |
PT2167121E (pt) * | 2007-06-26 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vacina compreendendo conjugados de polissacáridos capsulares de streptococcus pneumoniae |
EP2424562B1 (en) | 2009-04-30 | 2015-10-07 | Coley Pharmaceutical Group, Inc. | Pneumococcal vaccine and uses thereof |
AU2010301043B2 (en) * | 2009-06-22 | 2014-01-09 | Wyeth Llc | Compositions and methods for preparing Staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
TW201136603A (en) * | 2010-02-09 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition |
CN101785857B (zh) | 2010-03-05 | 2012-09-26 | 成都安特金生物技术有限公司 | 一种新的肺炎球菌结合疫苗及其制备方法 |
WO2011130332A1 (en) * | 2010-04-12 | 2011-10-20 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
WO2012078482A1 (en) | 2010-12-10 | 2012-06-14 | Merck Sharp & Dohme Corp. | Novel formulations which mitigate agitation-induced aggregation of immunogenic compositions |
GB201103836D0 (en) * | 2011-03-07 | 2011-04-20 | Glaxosmithkline Biolog Sa | Conjugation process |
BR112013024322B1 (pt) * | 2011-03-22 | 2020-04-22 | Serum Inst India Ltd | processo para preparação de polissacarídeos |
WO2013131983A1 (en) * | 2012-03-07 | 2013-09-12 | Novartis Ag | Adjuvanted formulations of streptococcus pneumoniae antigens |
KR102057217B1 (ko) * | 2012-06-20 | 2020-01-22 | 에스케이바이오사이언스 주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
ES2700824T3 (es) * | 2012-08-16 | 2019-02-19 | Pfizer | Procedimientos y composiciones de glucoconjugación |
CN103656631B (zh) * | 2012-09-24 | 2015-08-19 | 北京科兴中维生物技术有限公司 | 多价肺炎球菌荚膜多糖-蛋白缀合物组合物及其制备方法 |
GB201218660D0 (en) * | 2012-10-17 | 2012-11-28 | Glaxosmithkline Biolog Sa | Immunogenic composition |
JP2015534964A (ja) * | 2012-10-17 | 2015-12-07 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
KR20140075201A (ko) * | 2012-12-11 | 2014-06-19 | 에스케이케미칼주식회사 | 다가 폐렴구균 다당류-단백질 접합체 조성물 |
EP3363806B1 (en) * | 2012-12-20 | 2022-11-16 | Pfizer Inc. | Glycoconjugation process |
ITMI20130142A1 (it) * | 2013-01-31 | 2014-08-01 | Biosynth Srl | Vaccini glicoconiugati comprendenti unita' di base di un costrutto molecolare esprimente epitopi multipli incorporati |
US20150079132A1 (en) * | 2013-09-17 | 2015-03-19 | Path | Evoking protection against streptotoccus pneumoniae incorporating b-cell and t-cell pneumococcal protein antigens and pneumococcal polysaccharides delivered concomitantly |
CN103495161B (zh) | 2013-10-08 | 2019-06-18 | 江苏康泰生物医学技术有限公司 | 一种多元肺炎球菌荚膜多糖-蛋白质结合物的混合物及其制备方法 |
US11160855B2 (en) * | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
MX371454B (es) * | 2014-01-21 | 2020-01-29 | Pfizer | Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos. |
PE20212335A1 (es) * | 2014-01-21 | 2021-12-16 | Pfizer | Composiciones inmunogenicas que comprenden antigenos sacaridos capsulares conjugados y usos de los mismos |
RU2743793C1 (ru) * | 2014-01-21 | 2021-02-26 | Пфайзер Инк. | Капсульные полисахариды Streptococcus pneumoniae и их конъюгаты |
JP2017505792A (ja) * | 2014-02-14 | 2017-02-23 | ファイザー・インク | 免疫原性糖タンパク質コンジュゲート |
CN106879257B (zh) * | 2014-09-26 | 2020-08-11 | 马普科技促进协会 | 针对肺炎链球菌(Streptococcus pneumoniae)血清型8的疫苗 |
PT3244917T (pt) | 2015-01-15 | 2023-05-31 | Pfizer | Composições imunogénicas para utilização em vacinas pneumocócicas |
US10716839B2 (en) * | 2015-04-13 | 2020-07-21 | University Of Maryland, Baltimore | Compositions and methods for producing bacterial conjugate vaccines |
PT3313436T (pt) * | 2015-06-23 | 2021-02-25 | Biological E Ltd | Vacina de conjugado pneumocócico multivalente |
KR102225282B1 (ko) * | 2015-07-21 | 2021-03-10 | 화이자 인코포레이티드 | 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도 |
US11191822B2 (en) * | 2016-06-22 | 2021-12-07 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Pneumococcal polysaccharide-protein conjugate composition |
CN109862908B (zh) * | 2016-08-05 | 2023-05-02 | 圣诺菲·帕斯图尔公司 | 多价肺炎球菌多糖-蛋白质缀合物组合物 |
US11951165B2 (en) * | 2016-12-30 | 2024-04-09 | Vaxcyte, Inc. | Conjugated vaccine carrier proteins |
BR112019013475A2 (pt) * | 2016-12-30 | 2020-02-27 | Sutrovax, Inc. | Conjugados de polipeptídeo-antígeno com aminoácidos não naturais |
WO2018134693A1 (en) * | 2017-01-20 | 2018-07-26 | Pfizer Inc. | Immunogenic compositions for use in pneumococcal vaccines |
WO2018156491A1 (en) * | 2017-02-24 | 2018-08-30 | Merck Sharp & Dohme Corp. | Enhancing immunogenicity of streptococcus pneumoniae polysaccharide-protein conjugates |
MX2019009869A (es) * | 2017-02-24 | 2019-10-02 | Merck Sharp & Dohme | Formulaciones de vacunas de conjugado de neumococos. |
WO2018169303A1 (ko) * | 2017-03-15 | 2018-09-20 | 주식회사 엘지화학 | 다가 폐렴구균 백신 조성물 |
AU2018280272C1 (en) * | 2017-06-10 | 2021-05-06 | Inventprise, Inc. | Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity |
US20200330579A1 (en) * | 2017-10-04 | 2020-10-22 | Liffey Biotech Limited | Saccharide-polypeptide conjugate compositions and methods of use thereof |
CA3084436A1 (en) * | 2017-12-06 | 2019-07-18 | Merck Sharp & Dohme Corp. | Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof |
-
2016
- 2016-07-18 KR KR1020187004595A patent/KR102225282B1/ko active IP Right Grant
- 2016-07-18 JP JP2018502252A patent/JP6994453B2/ja active Active
- 2016-07-18 TW TW105122614A patent/TWI684460B/zh active
- 2016-07-18 AU AU2016295566A patent/AU2016295566B2/en active Active
- 2016-07-18 TW TW108111336A patent/TWI720448B/zh active
- 2016-07-18 SG SG10202005253TA patent/SG10202005253TA/en unknown
- 2016-07-18 CN CN201680054602.2A patent/CN108367063A/zh active Pending
- 2016-07-18 RU RU2018100123A patent/RU2721128C2/ru active
- 2016-07-18 KR KR1020237013256A patent/KR20230058726A/ko not_active Application Discontinuation
- 2016-07-18 NZ NZ739007A patent/NZ739007A/en unknown
- 2016-07-18 WO PCT/IB2016/054217 patent/WO2017013548A1/en active Application Filing
- 2016-07-18 EP EP16741695.7A patent/EP3325008A1/en active Pending
- 2016-07-18 TW TW107106645A patent/TWI684461B/zh active
- 2016-07-18 MX MX2018000867A patent/MX2018000867A/es unknown
- 2016-07-18 PE PE2018000092A patent/PE20180657A1/es unknown
- 2016-07-18 TW TW109137693A patent/TWI756893B/zh active
- 2016-07-18 MY MYPI2018700062A patent/MY192183A/en unknown
- 2016-07-18 CA CA2936378A patent/CA2936378A1/en active Pending
- 2016-07-18 BR BR112018000087-6A patent/BR112018000087A2/pt active Search and Examination
- 2016-07-18 IL IL303998A patent/IL303998A/en unknown
- 2016-07-18 KR KR1020217006257A patent/KR20210027523A/ko not_active IP Right Cessation
- 2016-07-20 AR ARP160102194A patent/AR105402A1/es unknown
- 2016-07-20 US US15/214,693 patent/US10124050B2/en active Active
-
2017
- 2017-12-28 IL IL256645A patent/IL256645A/en unknown
-
2018
- 2018-01-04 PH PH12018500037A patent/PH12018500037A1/en unknown
- 2018-01-10 ZA ZA2018/00197A patent/ZA201800197B/en unknown
- 2018-01-19 CO CONC2018/0000503A patent/CO2018000503A2/es unknown
- 2018-01-19 MX MX2021015775A patent/MX2021015775A/es unknown
- 2018-09-25 US US16/140,934 patent/US11020469B2/en active Active
-
2019
- 2019-01-04 HK HK19100160.3A patent/HK1257816A1/zh unknown
- 2019-06-06 ZA ZA2019/03620A patent/ZA201903620B/en unknown
- 2019-07-26 AU AU2019208271A patent/AU2019208271B2/en active Active
-
2021
- 2021-04-27 US US17/241,603 patent/US20210260177A1/en not_active Abandoned
- 2021-12-13 JP JP2021201968A patent/JP7268125B2/ja active Active
-
2023
- 2023-04-20 JP JP2023069532A patent/JP2023093636A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2018100123A (ru) | Иммуногенные композиции, содержащие конъюгированные антигены капсульного сахарида, наборы, содержащие эти композиции, и их применения | |
CO7461130A2 (es) | Composición multivalente de conjugados de proteína-polisacárido neumococico | |
AR116043A2 (es) | Composición de vacuna conjugada de polisacárido-proteína neumocócica 15-valente | |
PH12015501269B1 (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
PE20161095A1 (es) | Composiciones inmunogenicas que comprenden antigenos de sacaridos capsulares conjugados y uso de los mismos | |
JP2019526621A5 (ru) | ||
AR040922A1 (es) | Composicion inmunogenica multivalente, uso de la misma para la fabricacion de un medicamento y procedimiento para preparar dicha composicion inmunogenica multivalente | |
PH12014502843B1 (en) | Polyvalent pneumococcal polysaccharide-protein conjugate composition | |
NO20082647L (no) | Vaksine | |
HRP20230416T1 (hr) | Imunogeni pripravci, namijenjeni upotrebi u cjepivima protiv pneumokoka | |
EA201990126A1 (ru) | Поливалентная пневмококковая полисахаридно-белковая конъюгатная композиция | |
MX2020007939A (es) | Composicion del conjugado proteina-polisacarido multivalente nuemococica. | |
JP2019526620A5 (ru) | ||
TW200719911A (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
MX2009013949A (es) | Vacuna que comprende conjugados de polisacárido capsular de streptococcus pneumoniae. | |
AR127517A2 (es) | Composición del conjugado proteína-polisacárido multivalente neumocócica | |
RU2022110368A (ru) | Иммуногенные композиции, содержащие конъюгированные капсульные сахаридные антигены, и их применение | |
TH108545B (th) | สารผสมมัลติวาเลนท์นิวโมคอกคอลโพลีแซคคาไรด์-โปรตีนคอนจูเกต | |
EA201990131A1 (ru) | Поливалентная пневмококковая полисахаридно-белковая конъюгатная композиция | |
AR114442A1 (es) | Composición del conjugado proteína-polisacárido multivalente neumocócica | |
EA202091440A1 (ru) | Поливалентная противопневмококковая полисахаридно-белковая конъюгированная композиция | |
AR114355A1 (es) | Composición del conjugado proteína-polisacárido multivalente neumocócica | |
TH128171A (th) | องค์ประกอบวัคซีนคอนจูเกต 15-วาเลนท์ นิวโมคอคคอล โพลีแซคคาไรด์-โปรตีน |